Trial Profile
A Pilot Study of a GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With a PD-1 Blockade Antibody (Pembrolizumab) and a Macrophage Targeting Agent (CSF1R Inhibitor) for the Treatment of Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; IMC CS4 (Primary) ; Pembrolizumab (Primary) ; Tumour cell vaccine-GVAX (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Pharmacodynamics
- 26 Jan 2024 Status changed from active, no longer recruiting to completed.
- 05 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 05 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.